Related Experiment Video
Updated: Jan 27, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP
Beth E Zucconi1,2, Jessica L Makofske1,3, David J Meyers4
1Division of Genetics, Department of Medicine , Brigham and Women's Hospital , Boston , Massachusetts 02115 , United States.
Insights
Combining two small molecules, A-485 and I-CBP112, effectively inhibits prostate cancer cell proliferation by reducing p300/CBP epigenetic enzyme occupancy on chromatin.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- p300 and CBP are related histone acetyltransferase (HAT) enzymes crucial for gene regulation.
- Dysregulation of p300/CBP is implicated in various diseases, including cancer.
- p300/CBP possesses a HAT domain inhibited by A-485 and a bromodomain antagonized by I-CBP112.
Purpose of the Study:
- To investigate the synergistic effect of simultaneously inhibiting the HAT and bromodomain of p300/CBP.
- To determine the impact of combined inhibition on prostate cancer cell proliferation and gene expression.
- To analyze the effect of dual-domain inhibition on p300 chromatin occupancy.
Main Methods:
- Utilized small molecules A-485 (HAT inhibitor) and I-CBP112 (bromodomain antagonist).
- Assessed the combined effect on prostate cancer cell proliferation.
- Quantified p300 chromatin occupancy using molecular techniques.
- Measured mRNA levels of specific genes, including androgen-dependent and oncogenic targets.
Main Results:
- The combination of I-CBP112 and A-485 synergistically inhibited prostate cancer cell proliferation.
- Dual-domain inhibition led to a significant reduction in p300 chromatin occupancy compared to single-agent treatment.
- Combination therapy reduced mRNA levels of key prostate cancer genes like KLK3 (PSA) and c-Myc.
- Reduced mRNA levels correlated with decreased p300 occupancy at gene promoters.
Conclusions:
- Concurrent targeting of the HAT and bromodomain of p300/CBP offers a pharmacologic advantage in inhibiting prostate cancer.
- This dual-inhibition strategy effectively reduces cancer cell proliferation by altering p300 chromatin binding and gene expression.
- Targeting key epigenetic regulators like p300/CBP presents a promising avenue for cancer therapy.
Abstract:
p300 and CBP are highly related histone acetyltransferase (HAT) enzymes that regulate gene expression, and their dysregulation has been linked to cancer and other diseases. p300/CBP is composed of a number of domains including a HAT domain, which is inhibited by the small molecule A-485, and an acetyl-lysine binding bromodomain, which was recently found to be selectively antagonized by the small molecule I-CBP112. Here we show that the combination of I-CBP112 and A-485 can synergize to inhibit prostate cancer cell proliferation. We find that the combination confers a dramatic reduction in p300 chromatin occupancy compared to the individual effects of blocking either domain alone. Accompanying this loss of p300 on chromatin, combination treatment leads to the reduction of specific mRNAs including androgen-dependent and pro-oncogenic prostate genes such as KLK3 (PSA) and c-Myc. Consistent with p300 directly affecting gene expression, mRNAs that are significantly reduced by combination treatment also exhibit a strong reduction in p300 chromatin occupancy at their gene promoters. The relatively few mRNAs that are up-regulated upon combination treatment show no correlation with p300 occupancy. These studies provide support for the pharmacologic advantage of concurrent targeting of two domains within one key epigenetic modification enzyme.
Related Concept Videos
Co-activators and Co-repressors
Impedance Combination
Combination Of Resistors
Stresses under Combined Loadings
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...
tRNA Activation
Activation Energy

